ReP USP - Resultado da busca

Artigo de periodico
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial (2019)
Herbst, R. S; Baas, P; Perez-gracia, J. L; Felip, E; Kim, D. -W; Han, J. -Y; Molina, J. R; Kim, J. -H; Arvis, C. Dubos; Castro Junior, Gilberto de
Source: Annals of oncology. Unidade: FM
Subjects: IMUNOHISTOQUÍMICA, ANTINEOPLÁSICOS, NEOPLASIAS PULMONARES, CÉLULAS CULTIVADAS DE TUMOR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HERBST, R. S et al. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Annals of oncology, v. 30, n. 2, p. 281-289, 2019Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdy545. Acesso em: 06 nov. 2024.
APA
Herbst, R. S., Baas, P., Perez-gracia, J. L., Felip, E., Kim, D. -W., Han, J. -Y., et al. (2019). Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Annals of oncology, 30( 2), 281-289. doi:10.1093/annonc/mdy545
NLM
Herbst RS, Baas P, Perez-gracia JL, Felip E, Kim D-W, Han J-Y, Molina JR, Kim J-H, Arvis CD, Castro Junior G de. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial [Internet]. Annals of oncology. 2019 ; 30( 2): 281-289.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1093/annonc/mdy545
Vancouver
Herbst RS, Baas P, Perez-gracia JL, Felip E, Kim D-W, Han J-Y, Molina JR, Kim J-H, Arvis CD, Castro Junior G de. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial [Internet]. Annals of oncology. 2019 ; 30( 2): 281-289.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1093/annonc/mdy545
Artigo de periodico
Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC (2019)
Barlesi, Fabrice; Garon, Edward B; Kim, Dong-Wan; Felip, Enriqueta; Han, Ji-Youn; Kim, Joo-Hang; Ahn, Myung-Ju; Fidler, Mary Jo; Gubens, Matthew A.; Castro Junior, Gilberto de
Source: Journal of thoracic oncology. Unidade: FM
Subjects: NEOPLASIAS PULMONARES, QUIMIOTERAPIA, QUALIDADE DE VIDA, IMUNOHISTOQUÍMICA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BARLESI, Fabrice et al. Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC. Journal of thoracic oncology, v. 14, n. 5, p. 793-801, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jtho.2019.01.016. Acesso em: 06 nov. 2024.
APA
Barlesi, F., Garon, E. B., Kim, D. -W., Felip, E., Han, J. -Y., Kim, J. -H., et al. (2019). Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC. Journal of thoracic oncology, 14( 5), 793-801. doi:10.1016/j.jtho.2019.01.016
NLM
Barlesi F, Garon EB, Kim D-W, Felip E, Han J-Y, Kim J-H, Ahn M-J, Fidler MJ, Gubens MA, Castro Junior G de. Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC [Internet]. Journal of thoracic oncology. 2019 ; 14( 5): 793-801.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.jtho.2019.01.016
Vancouver
Barlesi F, Garon EB, Kim D-W, Felip E, Han J-Y, Kim J-H, Ahn M-J, Fidler MJ, Gubens MA, Castro Junior G de. Health-related quality of life in KEYNOTE-010: a phase II/III study of Pembrolizumab versus Docetaxel in patients with previously treated advanced, programmed death ligand 1-Expressing NSCLC [Internet]. Journal of thoracic oncology. 2019 ; 14( 5): 793-801.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.jtho.2019.01.016
Artigo de periodico
Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study (2019)
Cho, Byoung Chul; Obermannova, Radka; Bearz, Alessandra; Mckeage, Mark; Kim, Dong-Wang; Batra, Ullas; Borra, Gloria; Orlov, Sergey; Kim, Sang-We; Castro Junior, Gilberto de
Source: Journal of thoracic oncology. Unidade: FM
Subjects: NEOPLASIAS PULMONARES, PROTEÍNAS QUINASES, JEJUM, ALIMENTOS, GASTROENTEROPATIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHO, Byoung Chul et al. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study. Journal of thoracic oncology, v. 14, n. 7, p. 1255-1265, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jtho.2019.03.002. Acesso em: 06 nov. 2024.
APA
Cho, B. C., Obermannova, R., Bearz, A., Mckeage, M., Kim, D. -W., Batra, U., et al. (2019). Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study. Journal of thoracic oncology, 14( 7), 1255-1265. doi:10.1016/j.jtho.2019.03.002
NLM
Cho BC, Obermannova R, Bearz A, Mckeage M, Kim D-W, Batra U, Borra G, Orlov S, Kim S-W, Castro Junior G de. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study [Internet]. Journal of thoracic oncology. 2019 ; 14( 7): 1255-1265.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.jtho.2019.03.002
Vancouver
Cho BC, Obermannova R, Bearz A, Mckeage M, Kim D-W, Batra U, Borra G, Orlov S, Kim S-W, Castro Junior G de. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study [Internet]. Journal of thoracic oncology. 2019 ; 14( 7): 1255-1265.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.jtho.2019.03.002
Artigo de periodico
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (2019)
Burtness, Barbara; Harrington, Kevin J; Greil, Richard; Soulieres, Denis; Tahara, Makoto; Castro Junior, Gilberto de Castro ; Psyrri, Amanda; Baste, Neus; Neupane, Prakash; Bratland, Ase
Source: Lancet. Unidade: FM
Subjects: CARCINOMA DE CÉLULAS ESCAMOSAS, NEOPLASIAS DE CABEÇA E PESCOÇO, ANTICORPOS MONOCLONAIS, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BURTNESS, Barbara et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, v. 394, n. 10212, p. 1915-1928, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)32591-7. Acesso em: 06 nov. 2024.
APA
Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., Castro Junior, G. de C., et al. (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, 394( 10212), 1915-1928. doi:10.1016/S0140-6736(19)32591-7
NLM
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Baste N, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [Internet]. Lancet. 2019 ; 394( 10212): 1915-1928.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)32591-7
Vancouver
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Baste N, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [Internet]. Lancet. 2019 ; 394( 10212): 1915-1928.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)32591-7
Artigo de periodico
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (2019)
Mok, Tony S. K; Wu, Yi-Long; Kudaba, Iveta; Kowalski, Dariusz M; Cho, Byoung Chul; Turna, Hande Z; Castro Junior, Gilberto de; Srimuninnimit, Vichien; Laktionov, Konstantin K; Bondarenko, Igor
Source: Lancet. Unidade: FM
Subjects: NEOPLASIAS PULMONARES, IMUNOHISTOQUÍMICA, QUIMIOTERAPIA, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOK, Tony S. K et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, v. 393, n. 10183, p. 1819-1830, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(18)32409-7. Acesso em: 06 nov. 2024.
APA
Mok, T. S. K., Wu, Y. -L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., et al. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 393( 10183), 1819-1830. doi:10.1016/S0140-6736(18)32409-7
NLM
Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro Junior G de, Srimuninnimit V, Laktionov KK, Bondarenko I. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [Internet]. Lancet. 2019 ; 393( 10183): 1819-1830.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)32409-7
Vancouver
Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro Junior G de, Srimuninnimit V, Laktionov KK, Bondarenko I. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [Internet]. Lancet. 2019 ; 393( 10183): 1819-1830.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)32409-7
Artigo de periodico-carta/editorial
A importância da caracterização molecular no câncer de pulmão [Editorial] (2019)
Castro Junior, Gilberto de; Harada, Guilherme; Mello, Evandro Sobroza de
Source: Jornal brasileiro de pneumologia. Unidade: FM
Subjects: NEOPLASIAS PULMONARES, BIOMARCADORES, PROGNÓSTICO, PREDIÇÃO, BIOLOGIA MOLECULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CASTRO JUNIOR, Gilberto de e HARADA, Guilherme e MELLO, Evandro Sobroza de. A importância da caracterização molecular no câncer de pulmão [Editorial]. Jornal brasileiro de pneumologia. Brasilia Df: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1590/1806-3713/e20190139. Acesso em: 06 nov. 2024. , 2019
APA
Castro Junior, G. de, Harada, G., & Mello, E. S. de. (2019). A importância da caracterização molecular no câncer de pulmão [Editorial]. Jornal brasileiro de pneumologia. Brasilia Df: Faculdade de Medicina, Universidade de São Paulo. doi:10.1590/1806-3713/e20190139
NLM
Castro Junior G de, Harada G, Mello ES de. A importância da caracterização molecular no câncer de pulmão [Editorial] [Internet]. Jornal brasileiro de pneumologia. 2019 ; 45( 3):[citado 2024 nov. 06 ] Available from: https://doi.org/10.1590/1806-3713/e20190139
Vancouver
Castro Junior G de, Harada G, Mello ES de. A importância da caracterização molecular no câncer de pulmão [Editorial] [Internet]. Jornal brasileiro de pneumologia. 2019 ; 45( 3):[citado 2024 nov. 06 ] Available from: https://doi.org/10.1590/1806-3713/e20190139
Artigo de periodico
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies (2019)
Nosaki, Kaname; Saka, Hideo; Hosomi, Yukio; Baas, Paul; Castro Junior, Gilberto de Castro ; Reck, Martin; Wu, Yi-Long; Brahmer, Julie R; Felip, Enriqueta; Sawada, Takeshi
Source: Lung cancer. Unidade: FM
Subjects: NEOPLASIAS PULMONARES, CARCINOMA BRONCOGÊNICO, IMUNOTERAPIA, ANTICORPOS MONOCLONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NOSAKI, Kaname et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung cancer, v. 135, p. 188-195, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.lungcan.2019.07.004. Acesso em: 06 nov. 2024.
APA
Nosaki, K., Saka, H., Hosomi, Y., Baas, P., Castro Junior, G. de C., Reck, M., et al. (2019). Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung cancer, 135, 188-195. doi:10.1016/j.lungcan.2019.07.004
NLM
Nosaki K, Saka H, Hosomi Y, Baas P, Castro Junior G de C, Reck M, Wu Y-L, Brahmer JR, Felip E, Sawada T. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies [Internet]. Lung cancer. 2019 ; 135 188-195.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.lungcan.2019.07.004
Vancouver
Nosaki K, Saka H, Hosomi Y, Baas P, Castro Junior G de C, Reck M, Wu Y-L, Brahmer JR, Felip E, Sawada T. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies [Internet]. Lung cancer. 2019 ; 135 188-195.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.lungcan.2019.07.004
Artigo de periodico
Non-gastrointestinal stromal tumours soft tissue sarcomas: an update (2019)
Matos, Gustavo Duarte Ramos; Camargo, Veridiana Pires de; Munhoz, Rodrigo Ramella; Castro Junior, Gilberto de Castro
Source: Ecancermedicalscience. Unidade: FM
Subjects: SARCOMA, NEOPLASIAS DE TECIDOS MOLES, CÉLULAS ESTROMAIS, CÉLULAS-TRONCO, CÉLULAS DA MEDULA ÓSSEA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MATOS, Gustavo Duarte Ramos et al. Non-gastrointestinal stromal tumours soft tissue sarcomas: an update. Ecancermedicalscience, v. 13, 2019Tradução . . Disponível em: https://doi.org/10.3332/ecancer.2019.958. Acesso em: 06 nov. 2024.
APA
Matos, G. D. R., Camargo, V. P. de, Munhoz, R. R., & Castro Junior, G. de C. (2019). Non-gastrointestinal stromal tumours soft tissue sarcomas: an update. Ecancermedicalscience, 13. doi:10.3332/ecancer.2019.958
NLM
Matos GDR, Camargo VP de, Munhoz RR, Castro Junior G de C. Non-gastrointestinal stromal tumours soft tissue sarcomas: an update [Internet]. Ecancermedicalscience. 2019 ; 13[citado 2024 nov. 06 ] Available from: https://doi.org/10.3332/ecancer.2019.958
Vancouver
Matos GDR, Camargo VP de, Munhoz RR, Castro Junior G de C. Non-gastrointestinal stromal tumours soft tissue sarcomas: an update [Internet]. Ecancermedicalscience. 2019 ; 13[citado 2024 nov. 06 ] Available from: https://doi.org/10.3332/ecancer.2019.958

USP Schools

ReP

Filtros

Authors

Subjects

Source title

Funding Agencies